New agreement between LXRepair and Innopsys for the development of RAD-LX™

New agreement between LXRepair and Innopsys for the development of RAD-LX™

New agreement between LXRepair and Innopsys 2018 June

Innopsys and LXRepair entered an agreement in the context of  the development of LXRepair diagnostic test RAD-LX™. RAD-LX™ is intended to predict radiotherapy adverse effects in patients receiving radiotherapy. LXRepair clinical proof of concept study is conducted on 300 patients in collaboration with Pr N. Magné from Institut de Cancérologie Lucien Neuwirth and is almost completed.
LXRepair will use InnoScan scanner.
This project is supported by a Bpifrance innovation program.